High Response Rate in Heavily Treated Multiple Myeloma With Novel Drug Combination

Published Date: 10 Jan 2025

ORR of 80% at recommended dose of talquetamab, teclistamab but with high rates of grade 3/4 AEs

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Improved end-of-life conversations for cancer patients are identified by a new study.

2.

Cancer deaths expected to rise to over 18 million in 2050, nearly 75% more than in 2024

3.

New drug combination shows good results in patients with HPV-negative head and neck cancer

4.

Outcomes in Resected Melanoma Influenced by Timing of Recurrence

5.

The risk of cancer is decreased by following international health recommendations.


© Copyright 2025 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot